Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

A super-resolution microscopy technique offers an unparalleled glimpse into how monoclonal antibodies bind to their targets ...

In a recent article published in Nature Cancer, a multi-institutional research team led by The University of Osaka describes ...

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC). Under this ...

Speaking at a recent Technology Networks’ symposium, Dr. Jason Reeves explained how AI is changing the development of ...

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

For the third task, they will apply the AI technology to develop antibodies against cancer antigens and bacterial, viral and autoimmune targets. They will select one candidate antibody for ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...